SOUTH SAN FRANCISCO, Calif., Oct 20, 2011 (BUSINESS WIRE) --

Exelixis, Inc. (NASDAQ:EXEL) will release its third quarter 2011 financial results on Thursday, October 27, 2011, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archived replay of the webcast will be available on the Event Calendar page under Investors at http://www.exelixis.com and via phone until 11:59 p.m. EST on November 27, 2011. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 64691635.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at http://www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor Relations and Corporate Communications
cbutler@exelixis.com